{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-120257","form_type":"8-K","ticker":"IDYA","cik":"0001676725","company_name":"IDEAYA Biosciences, Inc.","filed_at":"2024-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.195945+00:00","generated_at":"2026-05-30T06:09:03.023244+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"IDEAYA reports Q3 net loss of $51.8M; cash $1.2B; progress in darovasertib and IDE397 trials","bullets":["Net loss of $51.8M for Q3 2024; R&D expenses $57.2M; G&A $9.7M.","Cash, equivalents and marketable securities of $1.2B as of Sep 30, 2024, up from $952.7M due to $283.8M follow-on net proceeds.","Darovasertib + crizotinib 1L UM registration trial enrollment exceeded 150 patients; successful FDA Type C meeting for neoadjuvant Ph3 targeting H1 2025 initiation.","IDE397 Phase 1 expansion at ENA 2024 showed 40% confirmed ORR in MTAP-deletion UC, 38% in squamous NSCLC, and 22% in adeno NSCLC.","IND clearance for IDE275 (Werner helicase) earned $7M milestone from GSK; targeting 3 DC nominations in Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-120257","json":"https://secwatch.observer/filing/0000950170-24-120257.json","markdown":"https://secwatch.observer/filing/0000950170-24-120257.md","text":"https://secwatch.observer/filing/0000950170-24-120257.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1676725/000095017024120257/0000950170-24-120257-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1676725/000095017024120257/idya-20241104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T06:09:03.023244+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}